Research Progress of DNA Methylation in Cisplatin Resistance in Lung Cancer.
10.3779/j.issn.1009-3419.2023.101.03
- Author:
Jinzhe SUN
1
;
Jun CHEN
1
Author Information
1. Department of Oncology, The Second Hospital of Dalian Medical University, Dalian 116000, China.
- Publication Type:Review
- Keywords:
Cisplatin;
DNA methylation;
Demethylation;
Drug resistance;
Lung neoplasms
- MeSH:
Humans;
Antineoplastic Agents/therapeutic use*;
Cell Line, Tumor;
Cisplatin/therapeutic use*;
DNA Methylation;
Drug Resistance, Neoplasm/genetics*;
Gene Expression Regulation, Neoplastic;
Lung Neoplasms/pathology*
- From:
Chinese Journal of Lung Cancer
2023;26(1):52-58
- CountryChina
- Language:Chinese
-
Abstract:
As one of the most common malignant tumors, lung cancer poses a serious threat to human life and health. The platinum-based drug cisplatin (DDP) is used as the first-line treatment for lung cancer. The poor prognosis of lung cancer is mostly due to developed resistance to cisplatin, which poses a serious treatment challenge. The mechanism of cisplatin resistance is complex and unclear. Numerous studies have shown that DNA methylation plays a crucial role in the emergence of lung cancer cisplatin resistance. DNA hypermethylation results in the deactivation of numerous drug resistance genes and tumor suppressor genes through a change in chromatin conformation. Finding new therapeutic targets and indicators to predict the therapeutic effect can be aided by elucidating the complex mechanism. In order to discover novel strategies to overcome cisplatin resistance in lung cancer, this paper discusses DNA methylation-mediated cisplatin resistance and offers an overview of current demethylation procedures.
.
